Bausch Health is being investigated by U.S. authorities in connection with marketing of four medicines used to treat different skin conditions, according to an internal document reviewed by STAT.
The Department of Justice sent a civil investigative demand last year to the company seeking information about various activities in which the medicines may have been promoted for uses not approved by regulators. The inquiry is focused on three drugs used to treat plaque psoriasis — Bryhali, Siliq, and Duobrii – and a fungal treatment called Jublia, the document stated.
Specifically, the Justice Department is interested in any financial assistance that may have been provided to Medicare patients who were prescribed Siliq, contracts or other documents in connection with compensation paid to physicians for helping to promote all four drugs through speaking and consulting work, and information concerning compliance with a regulatory safety and education program for Siliq.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
